08:34 AM EDT, 09/19/2025 (MT Newswires) -- Medtronic ( MDT ) said Friday that it has received US Food and Drug Administration approval for the Altaviva device, a minimally invasive implantable, tibial neuromodulation therapy device, which is inserted near the ankle and designed to treat urge urinary incontinence.

The company said the implant procedure does not require sedation or imaging and it is placed slightly below the skin but above the fascia.

Medtronic ( MDT ) said it sends electrical impulses to the tibial nerve, helping restore communication between the bladder and the brain to regulate bladder control.